Replies to post #1224 on Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

ABBV keep prices reasonable.

http://www.bloomberg.com/news/articles/2015-12-01/gilead-used-revenue-driven-pricing-on-hep-c-drug-senators-say?cmpid=yhoo.headline

That tough negotiating applied to the U.S.’s taxpayer-funded health programs, as well as private insurers. The company offered supplemental rebates of 10 percent to Medicaid, the state-run, U.S.-funded health insurance program for the poor, the senators said. Those rebates, however, came with the condition that states had to drop some or all of their access restrictions, according to the Senate investigation. Only five state Medicaid programs reached agreements to receive extra rebates in 2014, the Senate investigation found.
Prices only dropped for Gilead’s hepatitis drugs after a competing treatment from AbbVie Inc. entered the market in December 2014. That led to the nation’s largest drug benefit manager, Express Scripts Holding Co., making AbbVie’s drug Viekira Pak the preferred treatment for the most common sub-type of the virus, according to the statement.